Intraoperative Brainstem Auditory Evoked Potentials and Postoperative Nausea and Vomiting After Microvascular Decompression.

World Neurosurg

Department of Neurosurgery, Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggi-Do, South Korea; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea. Electronic address:

Published: May 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: We performed this study to investigate the effect of intraoperative brainstem auditory evoked potential (IBAEP) changes on the development of postoperative nausea and vomiting (PONV) after microvascular decompression (MVD) for neurovascular cross compression.

Methods: A total of 373 consecutive cases were treated with MVD. The use of rescue antiemetics after surgery was used as an objective indicator of PONV. IBAEP monitoring was routinely performed in all.

Results: The use of rescue antiemetics was significantly associated with female sex (OR = 3.427; 95% CI, 2.077-5.654; P < 0.001), PCA use (OR = 3.333; 95% CI, 1.861-5.104; P < 0.001), and operation time (OR = 1.017; 95% CI, 1.008-1.026; P < 0.001). A Wave V peak delay of more than 1.0 milliseconds showed a significant relation with the use of rescue antiemetics (OR = 1.787; 95% CI, 1.114-2.867; P = 0.016) and a strong significant relation with the use of rescue antiemetics more than 5 times (OR = 2.426; 95% CI, 1.372-4.290; P = 0.002).

Conclusions: A wave V peak delay of more than 1.0 milliseconds might have value as a predictor of PONV after MVD. More detailed neurophysiological studies will identify the exact pathophysiology underlying PONV after MVD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2024.03.041DOI Listing

Publication Analysis

Top Keywords

rescue antiemetics
16
intraoperative brainstem
8
brainstem auditory
8
auditory evoked
8
postoperative nausea
8
nausea vomiting
8
microvascular decompression
8
wave peak
8
peak delay
8
delay 10 milliseconds
8

Similar Publications

Background: The dopamine D2/D3 antagonist amisulpride has demonstrated its superiority and efficacy in prophylaxis of postoperative nausea and vomiting (PONV). Given the branded intravenous amisulpride (Barhemsys) has not been approved in China, there is unmet clinical need for amisulpride. Our primary objective was to ascertain the efficacy and safety of the generic intravenous amisulpride (QLG2069) in the prophylaxis of PONV.

View Article and Find Full Text PDF

Introduction:  Breast cancer incidence has been rising in recent years, particularly among younger women, and it is now the leading cancer among Indian females. Acute postoperative pain is a significant concern, often deterring patients from surgery. Combining regional anesthesia with intravenous analgesics can improve postoperative outcomes.

View Article and Find Full Text PDF

Background/aim: This study aimed to investigate the efficacy of olanzapine, an antiemetic agent used to prevent chemotherapy-induced nausea and vomiting (CINV), at 5 and 10 mg/day, by chemotherapy emetogenic risk, and to evaluate the efficacy of low dose olanzapine at 2.5 mg/day.

Materials And Methods: PubMed and Web of Science were searched to identify studies evaluating the efficacy of olanzapine in CINV prevention from database inception up to August 31, 2023.

View Article and Find Full Text PDF

Background: This phase I trial aimed to assess the pharmacokinetics (PK), safety, and preliminary efficacy of a single dose of HR20013 (mixed formulation of fosrolapitant and palonosetron) plus dexamethasone in patients with malignant solid tumors.

Methods: Solid tumor patients who were naive to cisplatin-based chemotherapy and scheduled to receive the single-day cisplatin-based chemotherapy were enrolled. Patients would receive a single intravenous infusion of HR20013 (Day 1) before cisplatin-based chemotherapy, alongside oral dexamethasone (Day 1, 12 mg, once a day; Day 2-4, 3.

View Article and Find Full Text PDF

Introduction: Obesity is a major global health issue requiring tailored anesthetic and analgesic strategies due to associated physiological and pharmacokinetic changes. The Enhanced Recovery After Bariatric Surgery (ERABS) protocol has been introduced to optimize perioperative care, but its implementation remains inconsistent. This pilot study investigates the integration of a perioperative clinical hypnosis (CH) protocol with ERABS to assess its effects on postoperative pain, nausea, and analgesic/antiemetic drug consumption in patients undergoing bariatric and metabolic surgery (BMS).

View Article and Find Full Text PDF